Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
Inflammatory Bowel Diseases
|
February 25, 2009
Low counts of Faecalibacterium prausnitzii in colitis microbiota
H Sokol, P Seksik, J P Furet, et al.
Current Opinion in Microbiology
|
July 9, 2013
Faecalibacterium prausnitzii and human intestinal health
S Miquel, R Martín, O Rossi, et al.
The Oncologist
|
October 29, 2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid
Martin H Cohen, Ramzi Dagher, Donna J Griebel, et al.
Journal of Clinical Pharmacology
|
August 1, 1978
Effect of abdominal radiation therapy on drug absorption in humans
G H Sokol, D J Greenblatt, B L Lloyd, et al.
Alimentary Pharmacology & Therapeutics
|
February 11, 2014
The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease
M Delvincourt, A Lopez, S Pillet, et al.
Neurogastroenterology and Motility
|
April 10, 2016
Interplay between bile acid metabolism and microbiota in irritable bowel syndrome
M Dior, H Delagrèverie, H Duboc, et al.
Neurogastroenterology and Motility
|
February 24, 2012
Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome
H Duboc, D Rainteau, S Rajca, et al.
Scientific Reports
|
January 19, 2016
Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models
S Miquel, R Martín, A Lashermes, et al.
Microbiome
|
April 22, 2024
Dissecting the respective roles of microbiota and host genetics in the susceptibility of Card9<sup>-/-</sup> mice to colitis
C Danne, B Lamas, A Lavelle, et al.
Journal of Clinical Microbiology
|
October 21, 2025
Serodiagnosis of amoebic abscess: a retrospective diagnostic accuracy study of kits marketed in Europe
E Prétot, M-P Brenier-Pinchart, P Tirard-Collet, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
Inflammatory Bowel Diseases
|
February 25, 2009
Low counts of Faecalibacterium prausnitzii in colitis microbiota
H Sokol, P Seksik, J P Furet, et al.
Current Opinion in Microbiology
|
July 9, 2013
Faecalibacterium prausnitzii and human intestinal health
S Miquel, R Martín, O Rossi, et al.
The Oncologist
|
October 29, 2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid
Martin H Cohen, Ramzi Dagher, Donna J Griebel, et al.
Journal of Clinical Pharmacology
|
August 1, 1978
Effect of abdominal radiation therapy on drug absorption in humans
G H Sokol, D J Greenblatt, B L Lloyd, et al.
Alimentary Pharmacology & Therapeutics
|
February 11, 2014
The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease
M Delvincourt, A Lopez, S Pillet, et al.
Neurogastroenterology and Motility
|
April 10, 2016
Interplay between bile acid metabolism and microbiota in irritable bowel syndrome
M Dior, H Delagrèverie, H Duboc, et al.
Neurogastroenterology and Motility
|
February 24, 2012
Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome
H Duboc, D Rainteau, S Rajca, et al.
Scientific Reports
|
January 19, 2016
Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models
S Miquel, R Martín, A Lashermes, et al.
Microbiome
|
April 22, 2024
Dissecting the respective roles of microbiota and host genetics in the susceptibility of Card9<sup>-/-</sup> mice to colitis
C Danne, B Lamas, A Lavelle, et al.
Journal of Clinical Microbiology
|
October 21, 2025
Serodiagnosis of amoebic abscess: a retrospective diagnostic accuracy study of kits marketed in Europe
E Prétot, M-P Brenier-Pinchart, P Tirard-Collet, et al.
Page
of 6